First-in-Class: Evaluating the Efficacy & Safety of an Oral Selective Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor in Dermatologic & Other Conditions
Time: 11:30 am
day: Day Two Translational Track AM
Details:
- Exploring the mechanism of action of deucravacitinib and its impact on biomarkers and clinical outcomes in psoriasis and psoriatic arthritis
- Delineating the distinct safety profile of deucravacitinib
- Dermatology and beyond: exploring TYK2 inhibition in other chronic inflammatory disorders
